VOYAGER
Research type
Research Study
Full title
A decentralised open label trial to eValuate the efficacy Of the VoY program in A patient population using GLP/GIP-1RA thERapy.
IRAS ID
350648
Contact name
Carel Le Roux
Contact email
Sponsor organisation
Menwell Ltd.
Duration of Study in the UK
2 years, 3 months, 1 days
Research summary
The aim of the trial is to find whether the Voy Program improves weight loss percentage and other health outcomes (blood pressure, cholesterol, blood glucose, quality of life, etc.) in a population that is taking GLP-1RA medication.
Obesity is a major health problem that affects many people; in 2022, about 64% of adults in England were either overweight or obese. Although obesity is common, the reasons behind it, its symptoms, and how best to treat it are complex and often debated. While the first steps to treat obesity involve improving diet, exercise, and lifestyle habits, studies show that focusing only on eating fewer calories and exercising more doesn’t usually lead to long-term weight loss.
Digital healthcare technologies could play a key role in changing how we prevent and treat obesity. Remote interventions, like online programs, offer several benefits over traditional methods. Digital solutions allow for personalised, interactive support, which makes it easier for patients to change their behaviour and improve results.
REC name
North West - Greater Manchester Central Research Ethics Committee
REC reference
24/NW/0378
Date of REC Opinion
20 Jan 2025
REC opinion
Further Information Favourable Opinion